Grupo de Investigación Pharmananogene

• Delgado D, Gascón AR, del Pozo-Rodríguez A, Echevarria E, Ruiz de Garibay AP, Rodríguez JM, Solinís MA  Dextran-protamine-solid lipid nanoparticles as a non-viral vector for gene therapy: In vitro characterization and in vivo transfection after intravenous administration to mice International Journal of Pharmaceutics,  2012;  425,  35 - 43
• Delgado D, del Pozo-Rodríguez A, SolinísMA, Avilés M, Weber BH, Fernández E, Rodríguez-Gascón A  Dextran and protamine-based solid lipid nanoparticles as potential vectors for the treatment of X linked juvenile retinoschisis Human Gene Therapy,  2012;  23,  355
• Isla A, Trocóniz IF, de Tejada IL, Vázquez S, Canut A, López JM, Solinís MÁ, Gascón AR  Population pharmacokinetics of prophylactic cefoxitin in patients undergoing colorectal surgery European Journal of Clinical Pharmacology,  2012;  68,  735 - 745
• Canut A, Isla A, Betriu C, Rodríguez-Gascón A.  Pharmacokinetic-pharmacodynamic evaluation of daptomycin, tigecycline and linezolid versus vancomycin for the treatment of MRSA infections in several Western European countries European Journal of Clinical Microbiology & Infectious Diseases,  2012;  31,  2227 - 2235
• Asín E, Isla A, Canut A, Rodríguez-Gascón A.  Comparison of antimicrobial pharmacokinetic/pharmacodynamic breakpoints with EUCAST and CLSI clinical breakpoints for Gram-positive bacteria International Journal of Antimicrobial Agents,  2012;  40,  313 - 322
• Ruiz de Garibay AP, Delgado D, del Pozo-Rodríguez A, Solinís MA, Gascón AR  Multicomponent nanoparticles as nonviral vectors for the treatment of Fabry disease by gene therapy Drug Design, Development and Therapy,  2012;  6,  303 - 310
• Calvo B, Zuñiga L.  The US approach to biosimilars: the long-awaited FDA approval pathway BioDrugs,  2012;  26,  357 - 361
• Calvo B, Zuñiga L.  Therapeutic monoclonal antibodies: strategies and challenges for biosimilars development Current Medicinal Chemistry,  2012;  19,  4445 - 4450